linjc16/ctgov huggingface dataset:
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without a rise in serum testosterone. The investigators expect testosterone will quickly and reliably reach castrate levels after initiation of ADT and will remain castrate during the transition, and there will be no testosterone surge after leuprolide injection.

Official Title
-----------------
Initiation of Androgen Deprivation Therapy for the Treatment of Prostate Cancer Using Degarelix Acetate Followed by Leuprolide Acetate

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: Degarelix acetate, Leuprolide acetate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older Histologically confirmed adenocarcinoma of the prostate Androgen deprivation therapy is indicated Exclusion Criteria: Baseline screening serum testosterone <150ng/dL Eastern Cooperative Oncology Group (ECOG) score > 2 Diagnosed spinal or brain metastases Hormonal manipulation within previous 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: ADT<br>All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot. | Drug: Degarelix acetate, Leuprolide acetate<br>* Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once<br>* Other names: Eligard;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Testosterone measurement |  | 11 times over 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate cancer, Hormone therapy, Testosterone measures
FRENCH OBSERVATORY OF ACUTE HEART FAILURE-2

Study Overview
=================
Brief Summary
-----------------
In 2009, OFICA 1 provided a snapshot of the management of acute heart failure in France. Over the past 10 years, practitioners have observed a change in the profiles of hospitalized patients and it is necessary to specify the evolution of these characteristics, especially since the recommendations concerning management have changed significantly; this is the objective of this observatory. Like patients suffering from chronic diseases such as diabetes or asthma, heart failure patients are therefore at the center of their management. Compliance is improved when patients have understood the reason for the prescription. Ideally, compliance should not be achieved by respecting externally imposed norms, but rather by respecting norms that are understood, adapted, personalized and accepted. A self-questionnaire will thus be given to patients on the day of inclusion in the study. In heart failure patients with an average age of 80 years, systematic screening for cognitive disorders using a simple test recommended by the French National Authority for Health (Haute Autorité de Santé), the codex test, will make it possible to offer more appropriate care if necessary (geriatric or neurology consultation). Finally, follow-up at 3 months and at 1 and 2 years will be carried out by matching with data from the National Health Data System (SNDS)

Official Title
-----------------
FRENCH OBSERVATORY OF ACUTE HEART FAILURE-2

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient hospitalized, regardless of the initial mode of admission, with acute heart failure (de novo heart failure or decompensation of chronic heart failure) of any severity and corresponding to one of the following clinical situations : Pulmonary edema, hypertensive or not Congestive heart failure (pulmonary congestion, peripheral oedema) Cardiogenic shock High output heart failure Isolated right heart failure Patient who agreed to participate in the study Exclusion Criteria: Expressed refusal to participate in the study Scheduled hospitalization for assessment Surgical context (immediate postoperative period) Diagnosis of acute heart failure reversed to another diagnosis before end of hospitalization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyze survival during hospitalization | Rate of death during hospitalizaton | Trough length of hospitalization, an average of 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyze survival at 2 years after hospitalisation | Rate of death at 2 years | 2 years after hospitalisation |
Effectiveness of Rotavirus Immunization in Nicaragua

Study Overview
=================
Brief Summary
-----------------
The purpose of the investigators study is to compare the rates of childhood diarrhea at the community level before and after the rotavirus vaccination program in León, Nicaragua. From preliminary studies, the investigators anticipate about a 28% reduction in diarrhea following the vaccination program among children who received the vaccine, and a smaller reduction in diarrhea among children who did not receive the vaccine, due to the effects of herd immunity. In addition, the investigators will collect stool samples from children who develop diarrhea in order determine the etiology of childhood diarrhea in the post-rotavirus immunization era.

Official Title
-----------------
Effectiveness of Rotavirus Immunization at the Community Level in Nicaragua

Conditions
-----------------
Diarrhea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age under 5 years, inclusion in health and demographic surveillance system (CIDS) in Leon, Nicaragua Exclusion Criteria: Parents do not consent to child's participation

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diarrhea, childhood, rotavirus, vaccine, Nicaragua
Ultrasound for Perfusion in Neonates

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effectiveness of renal ultrasound to check kidney perfusion in premature and/or very low birth weight babies.

Detailed Description
-----------------
The purpose of this study is to evaluate the effectiveness of 3D (3 dimensional)renal ultrasound to check kidney perfusion (to see if the kidney is receiving enough blood flow to function as it should) in premature and/or very low birth weight babies.

Official Title
-----------------
3D Ultrasound for Perfusion in Neonates

Conditions
-----------------
Kidney Perfusion

Intervention / Treatment
-----------------
* Procedure: 3D Ultrasound Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Very low birth weight babies in ICU in stable condition and/or premature babies in ICU in stable condition Exclusion Criteria: Unstable very low birth weight/premature babies

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 28 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Renal perfusion in Neonates<br>Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys. | Procedure: 3D Ultrasound Imaging<br>* Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine if ultrasound imaging can accurately help physicians determine if the kidneys are being adequately perfused. | Fractional blood volume was determined as a way to measure kidney perfusion. Adequate perfusion indicates that the kidneys are working and might indicate if a baby was responding to a specific treatment or not. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal, neonates
Body Parameters as an Independent Predictor of Acute Pancreatitis

Study Overview
=================
Brief Summary
-----------------
This study is to assess the predictive significance of visceral adipose tissue (VAT) and visceral adipose tissue /skeletal muscle tissue ratio (VAT/SMT ratio) for the prognosis in acute pancreatitis (AP) patients.

Detailed Description
-----------------
Acute pancreatitis (AP) is a sudden inflammation of the pancreas. However, one-fifth of patients may develop severe complications with a mortality between 10%-20% It remains a difficulty to find an effective method for prediction of severity of AP at early stage. It is well-established that obesity (defined as body mass index[BMI]>30kg/m2 by the World Health Organization) is a risk factor for AP and increases the incidence of systemic complication, motality. There are a lot of parameters related to saropenic obesity, including areas of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle tissue (SMT), and VAT/SMT ratio. it is unclear which parameter is the best predictor of severe AP. Thus, this study is aimed to investigate the association between these parameters and AP severity and find the best predictor of AP.

Official Title
-----------------
Body Parameters as an Independent Predictor of Acute Pancreatitis: A Propensity Score-matched Case-control Study

Conditions
-----------------
Acute Pancreatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed with AP age >18 years Exclusion Criteria: age<18years missing data in the electronic medical record history of AP

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparisons of variables according to AP severity | Comparisons of variables according to AP severity by one-way analysis of variance (ANOVA) and Likelihood Ratio | the physical examination data in the year of 2017 | 
| Relationships between VAT and severity outcomes Relationships between VAT and severity outcomes Relationships between VAT and severity outcomes Relationships between body parameters and severity outcomes | Relationships between VAT and severity outcomes by Likelihood Ratio | the physical examination data in the year of 2017 |
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Detailed Description
-----------------
Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam. Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation. Pts. with hepatobiliary neoplasia Pts.undergoing transjugular portosystemic shunt (TIPS) placement Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

Official Title
-----------------
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Conditions
-----------------
Liver Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated Exclusion Criteria: <18 yrs. of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Waitlist Mortality | Death prior to liver transplant or delisting from enrollment in the study | Measured up to 10 years out from enrollment |
Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare in patients with critical limb ischemia the efficacy of angioplasty with different paclitaxel-eluting balloon devices for below-the-knee lesions in terms of restenosis.

Detailed Description
-----------------
Two devices will be evaluated: the Lutonix and the Freeway paclitaxel eluting balloons. A post-hoc analysis will compare the results with the historical data from DEBATE-BTK (NCT01558505).

Conditions
-----------------
Peripheral Artery Disease

Intervention / Treatment
-----------------
* Device: Freeway PTA
* Device: Lutonix PTA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age>18 years angiographic stenosis>50% or occlusion of one below-knee vessel Exclusion Criteria: allergy to Paclitaxel contraindication for combined antiplatelet treatment life expectancy <1 year hypersensitivity or contraindication to one of the study drugs lack of consent need for amputation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Freeway<br>angioplasty with Freeway drug-eluting balloon | Device: Freeway PTA<br>* angioplasty with Freeway drug-eluting balloon<br>|
| Experimental: Lutonix<br>angioplasty with Lutonix drug-eluting balloon | Device: Lutonix PTA<br>* angioplasty with Lutonix drug-eluting balloon<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of events of angiographic binary restenosis | number of events of angiographic binary restenosis | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of events of target lesion revascularization | number of events of target lesion revascularization | 12 months | 
| number of events of death | number of events of death | 12 months | 
| frequency of major amputation | frequency of major amputation | 12 months |
Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes

Study Overview
=================
Brief Summary
-----------------
The optimal wavelength for phototherapy for neonatal jaundice remains to be clarified by clinical studies. Previous iv vivo studies have shown that turquoise light at wavelength about 490 nm is more efficacious than blue light at wavelength 460 nm, which is the golden standard in phototherapy treatment today. Though, previous studies used light tubes, today we use light emitting diodes (LED'S). The overall aim of this study was therefore to compare the efficacy of turquoise LED's versus blue LED's for decreasing total serum bilirubin in neonates with gestational age > 33 weeks and uncomplicated hyperbilirubinemia.

Official Title
-----------------
Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes

Conditions
-----------------
Uncomplicated Neonatal Hyperbilirubinemia

Intervention / Treatment
-----------------
* Other: Phototherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newborns with gestational age >33 weeks and neonatal hyperbilirubinemia requiring treatment with phototherapy according to the national guidelines Exclusion Criteria: Haemolytic disease (Rhesus and Kell blood type isoimmunization, spherocytosis) Liver disease

Ages Eligible for Study
-----------------
Minimum Age: 33 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Blue light wavelenght 460 nm<br> | Other: Phototherapy<br>* The infants were randomized to phototherapy with either blue og turquoise light<br>|
| Active Comparator: Turquoise light wavelength 499 nm<br> | Other: Phototherapy<br>* The infants were randomized to phototherapy with either blue og turquoise light<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in total serum bilirubin | The infants were treated with phototherapy for 24 hours, which is the standard treatment. | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neonatal hyperbilirubinemia, Phototherapy, Light emitting diodes, Blue light, Turquoise light
Factors Associated With Cesarean Delivery in Women With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
Introduction : Cesarean rate varies from 45% to 73% in the literature in patient with diabetes type 1. Having a prior C-section is the most important risk factor. The aim of this study was to identify risk factor of cesarean in this population. Methods: This study is an observational, retrospective and single-center study from the hospital of Montpellier. All the pregnancies, planned or not, with subcutaneous insulin infusion or multiple daily injections of insulin, in patients with diabetes type 1 between 2009 and 2015, after 24 weeks of gestation were included. All the data were retrospectively collected by the principal investigator with computer and paper files.

Official Title
-----------------
Factors Associated With Cesarean Delivery in Women With Type 1 Diabetes

Conditions
-----------------
Pregnant Women, Diabetes Type 1, Cesrean Delivery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women with diabetes type 1 Pregnancy initiated between 2009 and 2015 Pregnancy followed up in the universitary hospital center of Montpellier Exclusion Criteria: Women who deliver in an other center women with intraperitoneal injections of insulin twin gestation termination of pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors associated with a cesarean delivery in patients with diabetes type 1 | he statistical analysis was made with multiple logistic regression using SAS V9.1 and R V3.1.1 programs. | 6 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors associated with a planned cesarean delivery in patients with diabetes type 1 | the statistical analysis was made with multiple logistic regression using SAS V9.1 and R V3.1.1 programs. | 6 years | 
| Risk factors associated with an emergency cesarean delivery in patients with diabetes type 1 | the statistical analysis was made with multiple logistic regression using SAS V9.1 and R V3.1.1 programs. | 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Type 1, Cesrean delivery, Risks factors